Oncology PracticeFlurry of cancer drug endorsements from EU panelSeptember 20, 2021Breast CancerMetastatic Breast CancerLung Cancer
Oncology PracticeFDA approves first oral drug for NSCLC with EGFR Exon 20 insertionSeptember 20, 2021Lung Cancer
Oncology PracticeImmunotherapy for cancer patients with poor PS needs a rethinkSeptember 20, 2021Breast CancerMetastatic Breast CancerLung CancerGynecologic CancerGenitourinary CancerGastrointestinal CancerFollicular Lymphoma
Oncology PracticeDurvalumab combos beat monotherapy for unresectable stage 3 NSCLCSeptember 20, 2021Lung Cancer
Oncology PracticeMediastinal relapse risk lower with PORT, but no survival benefitSeptember 20, 2021Lung Cancer
Oncology Practice‘Urgent’ need to understand immunotherapy de-escalation in NSCLCSeptember 17, 2021Lung Cancer
Oncology PracticeTackling grief, loss in patients with advanced lung cancerSeptember 17, 2021Lung Cancer
Oncology PracticeESMO 2021: Impressive clinical research despite pandemicSeptember 16, 2021Lung Cancer
Oncology PracticeCombo treatment for NSCLC with brain metastases extends survival by two years for someSeptember 15, 2021Lung CancerCNS/Brain CancerHead & Neck/Thyroid Cancers
Oncology PracticePandemic strategies to boost trial enrollment should staySeptember 13, 2021Lung CancerCOVID-19 Updates
Oncology PracticeAir pollution – second leading cause of lung cancerSeptember 13, 2021Lung CancerPreventive Care
Oncology PracticeUnequal resource distribution underlies lung cancer disparitiesSeptember 10, 2021Lung CancerDiversity in Medicine
Oncology PracticeFinding the most bang for the buck with adjuvant atezolizumab for NSCLCSeptember 10, 2021Lung Cancer
